Opinion|Videos|May 6, 2024 (Updated: May 6, 2024)
Importance of Early Diagnosis of Alzheimer’s Disease
Key opinion leaders emphasize the significance of early diagnosis in Alzheimer's disease, as it allows patients to make autonomous decisions and access early treatment options, including potential participation in clinical trials.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- Discuss the importance of early diagnosis and treatment of Alzheimer’s disease.
Advertisement
Related to this article
Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.
Here's some of what is coming soon to NeurologyLive® this week.
The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.
Joanna Wardlaw, MD, Professor of Applied Neuroimaging at the University of Edinburgh, discusses the evolving understanding of cerebral small vessel disease, emerging therapeutic approaches, and the makings behind a successful trial.
Here's some of what is coming soon to NeurologyLive® this week.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery!
Two-year data from the phase 2 DAZALS trial showed a lower risk of death with dazucorilant 300 mg/day vs placebo in ALS, although the study did not meet its functional primary end point.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Grants Priority Review to Huntington Disease Gene Therapy BLA, Sevasemten Misses Primary, Secondary End Points in BMD, Overviewing the 1-Year KYSA-8 Findings
2
QurAlis Reports ANQUR Interim Data for STATHMIN-2-Targeting Agent QRL-201 in ALS
3
ALS Agent Dazucorilant Associated With Lower 2-Year Mortality in Exploratory DAZALS Analysis
4
Gray Areas: Is Preventing Frailty in Multiple Sclerosis a Realistic Goal?
5